Symptom Management Overview

Rasburicase is a recombinant urate oxidase that catalyzes the oxidation of uric acid into allantoin, a more soluble metabolite. Within hours of intravenous administration, rasburicase directly reduces serum uric acid concentrations, making it an essential therapy for the prevention and treatment of hyperuricemia in patients with tumor lysis syndrome (TLS).

For patients diagnosed with cancer, the annual incidence of VTE is approximately 20%, and the risk for VTE in this patient population is estimated to be 7 times higher than in the general population.

Targeting and inhibiting the vascular endothelial growth factor (VEGF)-signaling pathway has become an integral modality in the treatment of a variety of malignancies, including renal-cell carcinoma (RCC); glioblastoma; hepatocellular carcinoma; gastrointestinal stromal tumors; and colorectal, lung, gastric, and ovarian cancers.
This section provides a quick update of symptomatic conditions in oncology and their management. Readers are invited to submit brief updates following the guidelines at

Results 1 - 4 of 4